In a study designed to reveal the rates of blood-brain transfer and decarboxylation of flu oro L-3,4-dihydroxyphenylalanine (FDOPA), we discovered a major discrepancy between the DOPA decarboxylase activity reported in the literature and the rate of FDOP A decarboxylation measured in the study. "Donor" rats re ceived intravenous injections of 6 mCi fluorine-I8-labeled FDOPA. The donor rats synthesized methyl-FDOPA. Ar terial plasma, containing both FDOPA and methyl FDOPA, was sampled from the donor rats at different times and reinjected into "recipient" rats in which it cir culated for 20 s. The blood-brain clearance of the mixture of labeled tracers in the plasma was determined by an integral method. The individual permeabilities were de termined by linear regression analysis, according to which the average methyl-FDOPA permeability in the blood-brain barrier was twice that of FDOPA, which av-
The amino acid 3-(3,4-dihydroxyphenyl) L-alanine (DOPA) is an intermediate in the synthe sis of catecholamines from tyrosine. The positron emitting analogue of DOPA, e 8 F]fluoro-DOPA (FDOPA), first prepared by Firnau et ai. (1 973) , is a tracer of DOPA metabolism in brain (Garnett et aI., 1983a) . During positron tomography, the concen tration of e8F] in brain is determined at different times . Both DOPA and its metabolites are trans ported from the circulation to brain tissue by an endothelial membrane transporter of large neutral eraged 0.037 ml g -1 min -1. The permeability ratio was used to determine the fractional clearance from the brain of FDOPA (and hence of methyl-FDOPA), which aver aged 0.081 min -1. In the striatum, the measured average FDOPA decarboxylation rate constant (�) was 0.010 min -1, or no more than 1 % of the rate of striatal decar boxylation of DOPA measured in vitro and in vivo. We interpreted this finding as further evidence in favor of the hypothesis that striatum has two dopamine (DA) pools, of which only DA in the large pool is protected from metab olism. Hence, no more than 1 % of the quantity of fluoro DA theoretically synthesized was actually retained in striatum. Key Words: Amino acids-Blood-brain bar rier -Catechol-O-methyltransferase-DOP A de carboxyl ase-Dopamine-Fluoro-3 ,4-dihydroxyphenylalanine Positron emission tomography-Striatum. amino acids (Oldendorf and Szabo, 1976) . Numer ous amino acids compete for this non-energy requiring, sodium-independent trans port . FDOPA is thus trans ported into all regions of the brain, but is retained mainly in the caudate nucleus and puta men (Garnett et aI . , 198 4) .
The enzyme DOPA decarboxylase (EC 4. 1. 1.28), often called "DOPA/ S-H T" or "aromatic L-amino acid" decarboxylase because of its poor substrate specificity, catalyzes the formation of do pamine (DA) from DOPA (Lovenberg et aI . , 1962) . The as sumption that the retention of FDOPA-derived ra dioactivity in striatum effectively is irreversible and reflects DOPA decarboxylation is based on in vitro analyses of samples of striatum from rat (Chiueh et aI., 1986) and monkey (Firnau et aI . , 1987) where 6-eH]fluoro-DA (6-eH]FDA) and 6-e 8 F]FDA, re spectively, accounted for almost all of the striat al labeled fluorine during the first hour .
While fluorodihydroxy phenylacetic acid and flu-orohomovanillic acid in brain arise from the break down of FDA, methyl-FDOPA in brain may arise from FDOPA in brain or methyl-FDOPA in the cir culation. When peripheral DOPA decarboxylase ac tivity has been inhibited, the extracerebral metabo lism of FDOPA appears to be dominated by cate chol-O-methyltransferase (COM T), which exists in many tissues, including brain (Huh and Friedhof, 197 9; Cumming et al., 1987b) . The formation of me thyl-FDOPA is enhanced by the use of the periph eral decarboxylase inhibitor carbidopa (Claveria et al., 1973) , an analogue of a-methyl-DOPA. Carbi dopa is administered to inhibit the peripheral decar boxylation of FDOPA to FDA and hence to elevate the FDOPA concentration in plasma, but it also causes methyl-FDOPA levels to rise because more FDOPA is available for methylation. The methyl-FDOPA generated in peripheral tis sues enters brain via the circulation and, with the methyl-FDOPA formed in brain, interferes with the calculation of FDA formation by contributing to the total radioactivity measured in the brain. Ignorance of the speed at which methyl-FDOPA enters brain tissue has precluded accurate estimates in vivo of the fraction of radioactivity in brain attributable to methyl-FDOPA.
The brain radioactivity can be properly quantified only when the rates of transfer of all labeled sub stances in plasma are known. The purposes of the present study were to (a) quantitate the rate of gen eration and blood-brain transfer of plasma methyl FDOPA, and to relate the transfer to the blood brain transfer of FDOPA; and (b) measure the DOPA decarboxylase activity in brain on the basis of the known rates of entry of FDOPA and methyl FDOPA.
Current knowledge, however insufficient, of the transport and metabolism of FDOPA in brain can be summarized in a five-compartment model that in cludes the eight transfer coefficients shown in Fig.  1 . The model describes the methylation of FDOPA in the circulation (actually in peripheral organs), the loss of methyl-FDOPA from the circulation, the methylation of FDOPA in brain tissue, the ex change of FDOPA and methyl-FDOPA between the circulation and brain tissue, and the decarboxyl ation of FDOPA in the tissue. Because of the 2-h half-life of DA in brain, this model a priori includes no loss of FDA metabolites from brain.
In an FDOPA study, on the basis of the model, the ultimate goal is to obtain the best estimate of the rate of decarboxylation of FDOPA (�). However, to reach this goal, the number of parameters in the model must be reduced or several of the coefficients determined separately. First, in the present study, we determined the magnitude of kf?, the coefficient of methylation. Second, we established the relation between the parameters KP, kfj, K�, and J?t by measuring the unidirectional blood-brain clearance of FDOPA and methyl-FDOPA. Third, for the stri atum, we established the magnitude of �. In the application of the model, we assumed � to be neg ligible compared to kf?
THEORY Determination of k:?
Assuming simple first-order processes of methyl ation and elimination, the concentration of methyl FDOPA in the circulation is given by the equation where C� (t) is the methyl-FDOPA concentration, kf? the coefficient of methylation, C� (t) the plasma concentration of FDOPA as a function of time, and � 1 the coefficient of methyl-FDOPA clearance from the circulation. Following integration and di vision by the plasma time-concentration integral of methyl-FDOPA, we obtain a linear equation with kf?
as the slope and -� 1 as the ordinate intercept,
where R is the C�(1)1C�(n ratio and eD and eM are the normalized plasma time-concentration inte grals of FDOPA and methyl-FDOPA (Gjedde, 198 1, 1982; Patlak et aI., 1983) .
Determination of K? and Ktt
Details of the experimental determination of the initial unidirectional blood-brain transfer of tracers have been given previously (Gjedde et aI., 198 0) . Briefly, the blood-brain clearance of a tracer can be calculated by the equation (3) where Kl is the clearance, M(n the tracer content in brain, including the vascular space, Vo the vas cular (' 'initial" ) volume of distribution of the tracer in brain, and Ca(t) the tracer concentration in plasma as a function of time during the experiment. If the period of study is so short that little tracer escapes from brain, Kl is an accurate estimate of the unidirectional blood-brain clearance of the tracer. The individual brain contents of methyl FDOPA and FDOPA are given by rearrangement of Eq. 3,
and (5) where M�(n and M�(n are the extravascular con tents of methyl-FDOPA and FDOPA and Ktt and K? the blood-brain clearances of methyl-FDOPA and FDOPA. Addition of Eqs. 4 and 5 yields where M*(n is the total content of tracers recorded in brain, assuming FDOPA and methyl-FDOPA to be the only labeled tracers in the injectate that cross the blood-brain barrier. By division with f �C:dt, the time-concentration integral of the sum of la beled tracers in plasma, we derived a formula for the combined clearance of the two tracers,
wherefM andfD are the fractions of methyl-DOPA and FDOPA in the injectate. Dividing by fD, we obtained a linear equation with the parameters Ktt and KP,
where, as above, R is the ratio of the two labeled compounds in plasma. It will be shown below (Dis cussion) that the ratio between Ktt and KP must be a constant. The magnitudes of Ktt and KP were determined by linear regression of simultaneously determined values of Kj/ fD and R. The variablesfD and R were both measured by HPLC of plasma samples. For the determination of Kj by Eq. 3, Vo was assumed to equal the plasma volume of rat brain (0.007 ml g-l; Gjedde, 198 1).
Determination of kr and k'f
If the period of circulation of the tracer (s) is not sufficiently short, Eqs. 4 and 5 do not suffice to de scribe the efflux of the tracers from brain. In re gions of the brain where FDOPA is not metabo lized, IJ1 is zero (by definition). In these regions, � and IJt can be determined by solution of the equa tions and dM�(t)
where IJt and � are the relative clearances of me thyl-FDOPA and FDOPA from the tissue. It will be shown below (Discussion) that also the ratio be tween IJt and � must be a constant and that it must be identical to the ratio between Ktt and KP. If we call this constant q, Eqs. 9 and 10 can be solved for the total radioactivity in a region of brain where IJ1 is zero,
from which � and IJt ( = q�) can be determined by iteration when M*(n, C�(t), C�(t), C:(n, KP, q, and Vo are known. In that case, Eq. 11 has a single unknown (i.e., �). The value of Vo was again as-sumed to equal the plasma volume of rat brain cor tical tissue (0.007 ml g-l; see above).
Determination of k?
In a region of the brain where k? is not zero, k?
can be determined when KP, k!1, q, and Vo are known. If the metabolism is irreversible and metab olites do not leave the brain tissue, the accumulated metabolic product is given by the solution of the equation
where M�(t) is the regional content of FDOPA me tabolites. In that case, the extravascular content of FDOPA is given by
while the extravascular content of methyl-FDOPA is given by Eq. 9. This assumes that If{, the coeffi cient of methylation in brain tissue, is negligible compared to the magnitude of the coefficient of methylation in the periphery. This assumption will be examined below (Discussion). In the absence of any loss of FDOPA metabolites, the solution of Eqs. 9, 12, and 13 for the total content of tracers in a region of brain is as follows:
This equation has a single unknown, k?, when M*(n, C�(t), C�(t), C:(n, KP, k!1, q, and Vo are known.
Coefficients of variation
For the estimates of k!1, KPlk!1, and k?, coeffi cients of variation (CVs) were determined by simul taneously varying KP and q by ± 1 SD in the solu tions of Eqs. 11 and 14.
EXPERIMENTAL PROCEDURES
The experimental design is outlined in Fig. 2 . The study included 15 male Sprague-Dawley rats (3 donor rats and 12 recipient rats). The rats were fasted the night before the experiment. They were anesthetized with halothane (1%), and catheters were placed in two femoral arteries J Cereb Blood Flow Metab, Vol. 10, No. 5, 1990 Donor Rot 6mCi FDOPA I.v. Step 2: Five minutes after injection, an arterial sample from the donor rat was rapidly centrifuged. Concentrations of FDOPA and metabo lites in 100 fLl plasma were measured by HPLC.
Recipient Rats
Step 3: A 400-fLl bolus of remaining plasma from the donor rat was rapidly injected into the femoral vein of the first recipient rat, and arterial blood was continuously withdrawn at a known rate.
Step 4: Twenty seconds after injection, the recipient rat was decapitated, and a final arterial sample was obtained separately.
Step 5: Brain tissue, the withdrawn sample, and the final arterial sample were immediately assayed by 'I-emission spectrometry. Steps 6--8: Steps 1-5 were re peated at 35, 65, and 95 min after injection of FDOPA to the donor rat.
Step 9: At 141 min, the donor rat was killed and final arterial and tissue samples collected. The radioactivity in brain tissue and arterial samples was recorded by 'I-emission spectrometry. and a femoral vein. The rats were lightly restrained in plaster casts and allowed to recover for 3-4 h.
Donor rats
The metabolite methyl-DOPA was labeled with fluo rine-18 by in vivo O-methylation of FDOPA in the donor rats. The coefficient of peripheral methylation (�) was determined by HPLC analysis of plasma sampled from the donor rats at different times.
Thirty minutes after intraperitoneal administration of carbidopa (10 mg kg-I), the donor rats received 5-10 mCi of FDOP A with a specific activity of 300 mCi mmol-I.
One-milliliter samples of arterial blood were obtained from the donor rats 5, 35, 65, and 95 min after adminis tration of FDOPA. A 400-1-1-1 bolus of plasma from each blood sample was injected into each of the recipient rats. The water compartment of a donor rat of 300 g is roughly 200 ml. Thus, at 5 min, the radioactivity in 400 1-1-1 of plasma from the donor rat was 10 /-LCi. At 95 min, the radioactivity declined to 4 I-I-Cil400 1-1-1. In each plasma sample, individual plasma concentrations of FDOPA and its metabolites were measured by HPLC. Arterial blood time-activity curves of total radioactivity, FDOPA, and methyl-FDOPA were established on the basis of the ar terial samples and the HPLC measurements.
At the end of the experiment (when the last of the four recipient rats for each donor rat had been killed), seven regions of the brain of donor rats were prepared for im mediate recording of radioactivity by "{-emission spec trometry.
Recipient rats
The blood-brain barrier permeability of recipient rats was measured with the integral method in which the amount of tracer accumulated in brain during the tracer's circulation was compared to the time-concentration inte gral of the plasma concentration in the same period (Eq. 3). In the present application of the integral method, Eq. 3 yielded the average clearance of all tracers in the donor plasma administered to the recipient rats.
When the recipient rats were in steady state, the 4oo-/-Ll plasma bolus from the donor rat, containing the tracers under study, was rapidly injected into the femoral vein. Arterial blood was continuously withdrawn from a femo ral artery at a known rate (-0.1 ml min -I) during the 20-s circulation of the tracers. The exact withdrawal rate was computed by weighing the withdrawal syringe (Gjedde et aI., 1980) . With a ki{ value of 0.01 min-I (see below), the ratio between the tracers was likely to change by much less than 1% during the 20 s of circulation.
The experiment was terminated 20 s after the injection by decapitation with a rodent guillotine. A final arterial sample was obtained at this time. The radioactivities of samples of seven brain regions, the withdrawn blood, and the arterial blood samples separately at the end of the experiment were immediately recorded by "{-emission spectrometry and decay-corrected to the time of injection of FDOP A to the donor rat.
HPLC analysis of FDOPA and metabolites in plasma
The HPLC analysis yielded the ratio between FDOPA and methyl-FDOPA in the plasma of the donor rat, and hence in the injectate administered to the recipient rat.
The HPLC assay for FDOPA and FDOPA metabolites was performed on plasma deproteinized with equal amounts of 20% trichloroacetic acid and centrifugation for 2-3 min at 12,500 g. One milliliter of supernatant was injected into a reverse-phase column. The elution solvent was a 85:15 (wt/wt) mixture of buffer (0.1 M KH2P04, 0.1 roM ethylenediaminetetraacetate, 5 roM heptane sulfonic acid in demineralized water) and methanol. The pH of the buffer-methanol solution was adjusted to 4.1 with 1 M NaOH, and the solution was filtered through a 0.45-l-I-m Millipore membrane.
The flow through the radioactivity detector was 0.5 ml min -I. The elution order was confirmed by ultraviolet detection of authentic samples of FDOPA, FDA, and flu-oro norepinephrine at 254 nm. The elution volume and retention time of methyl-FDOPA were determined by comparing the methyl-DOPA retention with the retention of other nonfluorinated compounds (DA, norepinephrine, and DOPA). The elution order was always norepineph rine, DOPA, methyl-DOPA, and DA.
The HPLC assays were digitized by computer (highest peak 100%). The two main peaks reflecting FDOPA and methyl-FDOPA were integrated to yield the relative amounts of individual tracers in the plasma sample. Other small peaks within the area of integration were subtracted by the computer.
Synthesis of FDOPA
Tracer FDOPA was prepared by reaction of 4,5dimethoxy-2-trifluoroacetoxymercuri-N-trifluoro acetylphenyl-L-alanine (100 /-Lmol; supplied by Bis Chern Inc., Montreal) with [18F]CH3COOF ([18F]acetylhypo fluorite) in chloroform (7 ml) at room temperature (Luxen et aI., 1986) . The acetylhypofluorite in neon was bubbled through a solution of the mercury compound at a flow of 70 ml min -I. After bubbling, the solvent was evaporated and the residual dissolved in dimethylether (4 ml) and passed through a small silica gel column to remove any unreacted mercury compound as well as any inorganic mercury byproducts formed during the fluorination. After evaporation of the ether, the residual was hydrolyzed in a mixture of 2 m157% HI and 1.2 ml acetic anhydride for 20 min in an oil bath at 145°C, under an inert atmosphere. At the end of the hydrolysis, the liquid was evaporated and the residual dissolved in 0.1 % acetic acid. This solution was injected into an HPLC reverse-phase silica column. The solvent was 0.1 % acetic acid flowing at 2 ml min -I. The major radioactivity peak was collected, the volume was reduced to -2 ml, and the solution was made isotonic by addition of 18 mg NaCI and finally sterilized by filtra tion through a 0.22-l-I-m Millipore membrane.
Chemicals
Carbidopa [(S)-a,4-dihydroxy-a-methylbenzenepro panoic acid monohydrate], in the form of powder, was a gift from Merck and Co. (Canada). The powder was dis solved in isotonic saline at 37°C before injection.
RESULTS

FDOPA and methyl-FDOPA concentrations in plasma
The fractions of FDOPA and methyl-DOPA of the total concentration of tracers in plasma of the three donor rats at 5, 35 ,65 , and 95 min, determined by HPLC analysis, are shown in Fig. 3 .
The actual radioactivities of methyl-FDOPA and FDOPA in plasma, as functions of time of circula tion in the donor rats, are shown in Fig. 4 . Five minutes after the injection of FDOPA, the concen tration of methyl-FDOPA was low. The concentra tion increased rapidly with time, reflecting metabo lism in peripheral organs, mainly liver. The concen tration reached an apparent steady state maintained by the decreasing concentration of the precursor and the redistribution of both compounds to tissues, including brain. The plateau suggested that the clearance of methyl-FDOPA from the circulation is slow.
Determination of k:?
The Time (minutes) indicated that the experiment was not well condi tioned for the determination of this variable.
Blood-brain transfer of FDOPA and methyl-FDOPA (KP and Kr) The clearance of the sum of tracers (Kj) was cal culated from Eq. 3. The individual clearances of FDOPA and methyl-FDOPA, calculated from Eq. 8 by linear regression, are listed in Table 1 for seven brain regions. A representative plot of Eq. 8 is shown in Fig. 6 . The regional clearance of FDOPA varied from 0. 02 5 to 0. 082 ml g-I min -I, the re gional clearance of methyl-FDOPA from 0. 0 52 to 0. 098 ml g-I min -I. With the exception of hypo thalamus, which has parts with a leaky blood-brain barrier (circumventricular organs), the ratio be tween the regional clearances varied from 1.7 ± 0.6 to 3.2 ± 2.4, albeit not significantly since the former distribution was contained in the latter. The total weighted blood-brain clearances of fluoro-L-DOPA and methyl-FDOPA averaged 0. 037 and 0. 083 ml g -1 min -I, respectively, and the weighted ratio be tween the whole-brain clearances, i.e., q, averaged 2.3.
Steady-state distribution of [ 18 F] in donor rats and determination of kr and �
The donor rats were killed 13 5-14 5 min after in jection of FDOPA. The volumes of distribution of 1 8F in seven brain regions (striatum plus the average of six nonstriatal regions) of donor rats at this time are shown in Fig. 7 . The steady-state distribution volume of the tracers averaged 0. 56 ± 0. 03 (SD) ml g -I in the extrastriatal regions, varying from 52 to 66% of the distribution in striatum. assumed that no FDOPA metabolites were formed in brain outside the striatum and that no methyl FDOPA was formed in brain anywhere. The value of J!i was calculated for the six extrastriatal regions by means of Eq. 11. The value averaged 0.081 ± 0.0001 (SD) min -I for the six regions. The value of 1Ct, calculated by multiplying the ratio q with the value of kr, averaged 0.18 5 min-I. The Kplkr (=Kr'"IICt) ratio averaged 0.46 ± 0. 03 ml g-I.
Determination of k?
The radioactivity distribution volume in the stri atum averaged 0.92 ± 0.02 (SD) ml g -I. Using the values of KP and J!i determined above, we calcu lated the value of J!j, the coefficient of metabolism of FDOPA, using Eq. 14. The value averaged 0. 01 0 ± 0.002 (SD) min -I. All estimates of transfer coef ficients have been listed in Table 2 .
The CV s of the parameter estimates, based on the direct measurements of KP and q, have been listed in Table 2 . The CV s of the estimates of J!i and k?
were similar to those of KP and q, indicating little propagation of error. In fact, the influence of the estimates of KP and q on the variability of the esti mates of kr and k? was minimal. The chief influ ence on the variability of J!i and k? arose from the estimate of the KPIJ!i ratio for which a 7% CV re sulted in a 42% CV for J!i (arising from KP) and a 33% CV for k?
Simulated brain time-activity curves for total ra dioactivity, FDOPA, methyl-FDOPA, and FDOPA metabolites were prepared with these estimates, one set representing striatum (Fig. 8, left) and one set representing extrastriatal tissue (Fig. 8, right) .
DISCUSSION
The primary findings of the present study include values for kf:, KP, J!i, and k? of FDOPA and Kr'" and ICt for methyl-FDOPA. In the following, we focus the discussion on the consequences of the astoundingly low value of k?, considering the cur rent assumption of negligible DOPA levels in stria tum.
Estimate of k�
Numerous reports have indicated that an 0methylated derivative is a prominent metabolite in blood plasma of humans (Boyes et al., 1986) or rats given FDOPA (Cumming et aI., 1987a) , fluoro eH]DOPA (Chiueh et aI., 1984) , or eH]DOPA (Horne et aI., 1984) . This derivative, methyl-DOPA or methyl-FDOPA, is the product of the reaction of DOPA or FDOPA with COM T in peripheral tissues. In the periphery, FDOPA is also subject to decar boxylation by DOPA decarboxylase. However, by inhibition of peripheral DOPA decarboxylase with carbidopa, FDOPA levels remain high, more FDOPA is O-methylated, and plasma levels of me thyl-FDOPA rise both in the circulation and in brain. This may appear to be a reason for avoiding the administration of carbidopa (Hoffman et al., 1987) , but the situation is more complicated: With carbidopa, only two major compounds exist in plasma, while without carbidopa, at least three must be taken into account, although at a lower concentration of methyl-FDOPA. FDOPA labeled in the 6-position has been re ported to have a relatively low substrate affinity for the O-methylating en zyme in vitro (Creveling and Kirk, 1985 ) . However, the present results confirm rapid methylation in vivo, as reported previously in studies in rats (Cumming et aI., 1987a) , monkeys (Comi et aI., 198 9) , and humans (Boyes et aI., 1986) . The present study also confirms the presence of only one major metabolite, methyl-FDOPA, ill plasma of rats pretreated with carbidopa. The present study represents the first determina tion of the relationship between FDOPA and meth yl-FDOPA permeability of the blood-brain barrier. Both FDOPA and methyl-FDOPA are subject to facilitated diffusion across the blood-brain barrier, utili zing the transporter of large neutral amino acids (Oldendorf and Szabo, 1976) . One common trans porter implies that other large amino acids normally present in plasma must compete with FDOPA and methyl-FDOPA for transport and hence inhibit the transfer of the tracers.
The competition may reduce the clearance of both tracers, but it does not affect the ratio between their clearances, according to the Michaelis-Menten kinetics of simple inhibition, applied to facilitated diffusion. It has been shown previously that both the ratio between the blood-brain clearances, as well as the partition volume (K1lk2), are indepen dent of the individual concentrations of the compet itors (Reith et aI., 1987) . This proof will be reiter ated briefly here.
The permeability-surface area product (P S) of a tracer subject to facilitated diffusion has been de rived previously (Pardridge and Oldendorf, 1975 ; Gjedde, 1981) ,
( 1 5) where Kt is the Michaelis half-saturation of the tracer, Cj the concentrations of all competitors in plasma, and Kj their inhibitory constants. The clear ance of the tracer is a function of the PS and the plasma flow, as derived by Crone (1 963),
where F is the plasma flow. When the permeability is low, i.e., when the PS is ,,;;; 10% of blood or plasma flow, the clearance approaches the perme ability-surface area product (capillary diffusion ca pacity). Since, as shown in this report, values of Kl Normalized Integral (minutes) 71 5
FIG. 8. Volumes of distribution (ordinate, ml g-1) of tracers in striatum (left) and extrastriatal brain regions (right) as function of normalized plasma integral of total radioactivity in plasma (abscissa, min) in donor rats, calculated from estimates of transfer coefficients listed in Table 2 , and the tracer concentrations in plasma shown in Fig. 4 , using Eqs. 11 and 14. FDA, fluorodopamine; FDOPA, fluoro-L-3,4-dihydroxyphenylalanine.
for fluoro-DOPA and methyl-DOPA do not exceed 20% of the normal magnitude of F, the plasma flow in rats, Eq. 16 reveals that 1 98 0) . The average for five monkeys was 0. 04 5 ml g-I min -I, in excellent agreement with the present study, but no correction was made for the synthesis of methyl-FDOPA and no carbi dopa was given. A Kp value can also be calculated for humans from data published by Leenders et al.
( 1 986). The values are 0. 01 4 ml g-I min-I for cau date-putamen and 0. 01 5 ml g-I min-I for cortex (Gjedde, 1988) , i.e., somewhat lower than in the present study of rats. Our finding of twofold higher uptake of methyl-FDOPA com pared to FDOPA in brain is in accordance with the measurements of ( 1 9) which is a constant, independent of blood and plasma flow changes as well as of changes of inhib itor concentrations. Wade and Katzman (1975b) 14C-Iabeled methyl-DOPA and DOPA (Wade and Kat zman, 197 5a , b) .
Estimates of !Ci and �
The magnitude of kf and � for extrastriatal tis sue was determined in the present study on the as sumption that the ratio between the values for the two tracers must be the same for k2 as for K 1 and that the coefficients of metabolism (kP and /Is') are both negligible outside striatum. As in the case of transfer into the brain, the former assumption was based on the application of Michaelis-Menten kinet ics to the transport of large neutral amino acids, but in this case in the direction from brain to blood. Using Eqs. 15 and 18 for both directions of transport across the blood-brain barrier, Gjedde and Diemer
(1 983) showed that the KI/k2 ratio (partition volume) for substrates transported by the same transporter in the blood-brain barrier must be the same, and equal to (Reith et al., 1987; Gjedde, 1988) 
where M i represents the tissue quantities (f.Lmol g-I) of substrates for the large neutral amino acid transporter and Vd the water volume of the tissue. Hence, the partition volume depends on the total large neutral amino acid gradient between plasma and tissue and it must be the same for all large neu tral amino acids. No term in Eq. 20 is specific for any single large neutral amino acid. Thus, when the KI/k2 ratio is the same for all substrates of the same transporter, we can conclude that �/kf ratio must equal the Ktt/KP ratio. The K,/k2 ratios recorded in the present study were somewhat lower than expected ( �O. 5 ml g -').
In one previous study, the partition volume of "cycloleucine," a nonmetaboli zable analogue of the large neutral amino acids, was close to the water volume of brain tissue (� 0.8 ml g -I) and hence re flected the absence of a concentration gradient be tween the sums of large neutral amino acids in blood plasma and brain tissue (Gjedde and Bodsch, 1987) . The lower partition volume in the present study probably does not reflect the dose of FDOPA that would tend, initially, to elevate the total plasma concentration of large neutral amino acids by no more than 10% (see below).
Estimate of k?
The steady-state volume of distribution of the ra dioactivity in striatum was almost twice as high as in extrastriatal tissue. Yet, the magnitude of kP de termined from the volume of distribution in striatum J Cereb Blood Flow Metab, Vol, 10, No.5, 1990 was unexpectedly low. The expectation was based on (a) in vitro estimates of the V max and Km of DOPA decarboxylase for DOPA and (b) estimates of the net rate of DOPA synthesis and DOPA levels recorded in striatum. When DOPA levels are much lower than the Km of the en zyme, and when FDOPA is an "ideal" tracer, i.e., a tracer for which the V max and Km of DOPA decarboxylase are the same as for DOPA, the kP should equal the V max/Km ratio of DOPA decarboxylase as well as the ratio between the rate of DA synthesis and the DOPA levels in the steady state. Both predictions were based on the definition of k3 for native DOPA, de rived from Eq. 12 and reflecting the simplest com petitive en zyme kinetics, where V max is the maximal velocity of the native reaction in vivo, V the velocity of native DA syn thesis in vivo, M e the native DOPA content of the tissue, Km the Michaelis half-saturation concentra tion of native DOPA, Vd the water volume, MI the quantities of all inhibitors in the tissue including DOPA itself and FDOPA, and KI the inhibitory con stants of the inhibitors. a. The Vmax and Km values of DOPA decarbox ylase for DOPA in vitro are known (1 00 nmol g -1 min-I and 100--200 f.L M, respectively; see Table 4 ); on the basis of these values, the k3 for DOPA is close to 1 min -I, or 100 times the value for FDOPA determined here.
b. The rate of DOPA accumulation has been mea sured after inhibition of DOPA decarboxylase and provides a lower estimate of the flux through the DA synthetic pathway at steady state (v). Table 5 lists recent estimates of the net rate of DOPA ac- (1985) 0.18 Reches et aI. (1985) 0.50 38 Myers and Pugsley (1986) 0.27 49 Galloway et al. (1986) 0.17 72 Milner et aI. (1987) 79 Average 0.28 48 cumulation in rat striatum. Also, the DOPA level in rat striatum was determined recently and averaged 0.4 nmol g-1 (Nissbrandt and Carlsson, 1987) . If 0.3 nmol g-I min -1 is chosen as a reasonable average for the steady-state rate of DA synthesis (see Table  5 ), the ratio between DA synthesis and the DOPA level again is close to 1 min -I. As a first explanation of the difference of two orders of magnitude, it is possible that the magni tude of JJ1 was low because it represents not DOPA decarboxylase activity but some other step in the transfer of the label. It is a consequence of the model used to estimate JJ1 that the higher volume of distribution of labeled materials in the striatum re flects the presence of a kinetic ' 'trap" in this region. As in the case of other tracers of en zymatic activity (e.g., deoxyglucose and fluorodeoxyglucose as tracers of hexokinase), the trap is set by the first irreversible en zymatic reaction. In the case of FDOPA, this en zyme is DOPA decarboxylase in the terminals of monoaminergic pathways (DA, norepinephrine, and serotonin). The model ex cludes any barriers to the transfer of the tracer be tween the extracellular space and the intracellular locus of the en zyme, but the assumption has not been validated for FDOPA. However, we know of no irreversible membrane transfer of DOPA that is specific for striatum.
If we accept that the trap is indeed DOPA decar boxylase, then the definition of JJ1 for FDOPA fol lows the definition of k3 for DOPA,
where V�ax is the maximal velocity of the tracer reaction in vivo and K� the Michaelis half saturation concentration of the tracer.
MI represents the quantities of all inhibitors in the tissue, including FDOPA. It follows that JJ1 may have been low because of inhibition of the en zyme by other substrates or by FDOPA itself. The quan tities of native inhibitors are not known with cer tainty. The substrates with the highest affinity for DOPA decarboxylase include a-tyrosine, an artifi cial amino acid; DOPA, of which the concentration is < 1 nmol g -1, as discussed above; and 5hydroxy tryptophan, of which there is probably even less in monoaminergic neurons, serotonergic or otherwise (Lovenberg et aI., 1962) . Other poten tial substrates are believed to have affinities too low to inhibit the en zyme significantly, although little recent evidence exists in the literature. The dose of radioactive FDOPA delivered to the donor rat was possibly sufficiently large to self inhibit the DOPA decarboxylase (i.e., MI may not have been negligible as required of a tracer). At a specific activity of 300 mCi mmol -1, the 6-mCi bo lus represented 20 /-Lmol. However, when dissolved in 200 ml water, the FDOPA attained an initial con centration of no more than 100 /-LM, which is similar to the 100 to 200 /-LM Km of DOPA and therefore likely to inhibit the en zyme by no more than 50%. At 14 0 min, the concentration was reduced to 13 /-LM in plasma, which was even less likely to cause significant inhibition. On the other hand, a tissue concentration of FDOPA that may have varied be tween 10 and 100 /-LM would generate FDA at a rate exceeding the rate of native DA synthesis by 1 to 2 orders of magnitude.
Then, the estimate of the magnitude of JJ1 may have been low because the affinities of DOPA and FDOPA for DOPA decarboxylase differed substan tially. However, the findings listed in Table 4 indi cate that the affinities of DOPA and FDOPA are close.
Finally, we were left with the possibility that the duration of the experiment may have been so long that significant quantities of FDOPA metabolites were lost to the circulation. A priori, however, this explanation was very unlikely for the following rea sons.
Calculated as the ratio between the DA turnover and DA concentration in striatum (Table 5) , the rate of turnover of DA is low, or <0.0 1 min -I, indicat ing a half-life of DA of ;;.2 h. To this value must be added the transit time through the DA metabolite pools and diffusion of metabolites to the CSF space from which they are transported by the choroid plexus. The FDA that entered a 48 nmol g-l DA pool could not, on this basis, be 99% metabolized in 2 h. The values suggest the presence of two pools of DA, of which only the larger pool effectively tra ps the label. If this explanation is correct, only 1 % of the newly formed FDA entered the larger pool while the rest was metaboli zed and removed ra pidly from the striatum. The explanation agrees with ev idence in the literature suggesting the presence of two pools of DA, one large and static, the other small and dynamic (Besson et aI . , 1969; Nissbrandt and Carlsson, 1987) .
The hypothesis of two DA pools does not explain why 99% of all FDA synthesi zed in the striatum was metaboli zed rapidly without entering the large pool. If the large pool resides in vesicles, as indicated by Garnett et al. (1 978, 1983 b) , then our findings strongly suggest that the rate of DA incorporation into vesicles were limited to the normal flux of DA and thus could not accommodate the much greater synthesis of FDA occurring in these experiments . Thus, the retention of FDOPA-derived radioactiv ity in striatum reflects only the small fraction of newly synthesi ze d DA that enters a large static pool of DA. For reasons that are unknown at this time, the maj or fraction of newly synthesi zed DA func tions as an overflow or safety valve of considerable capacity .
